权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity

胰腺癌恶性细胞状态的基质调节和治疗敏感性

基本信息

批准号：
10517569
负责人：
Andrew James Aguirre
金额：
$ 103.7万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-19 至 2027-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10517569
关键词：
Affect Aftercare Antibodies Archives Biology Biopsy Cell Nucleus Cells Cellular Structures Clinical Clinical Trials Coculture Techniques Complex Data Dermal Disease Progression Disease Resistance Evolution Exhibits Fibroblasts Gene Expression Genetic Screening Genetically Engineered Mouse Genomic approach Growth Factor Heterogeneity Human Hypoxia Immunofluorescence Immunologic Impairment Investigation Isogenic transplantation Ligands Light Liver Malignant Neoplasms Malignant neoplasm of pancreas Mesenchymal Metastatic Neoplasm to the Liver Modeling Nature Neoadjuvant Therapy Neoplasm Metastasis Nutrient Organ Organoids Pancreatic Ductal Adenocarcinoma Patients Pattern Pericytes Pharmaceutical Preparations Phenotype Play Population Prior Therapy Process Proteins Resistance Role Sampling Shapes Signal Transduction Small Nuclear RNA Specimen Stromal Cells TGFB1 gene Testing Therapeutic Tumor Subtype Work base biobank cancer cell cell type chemotherapy cytokine differential expression digital functional genomics innovation insight member multidisciplinary neoplastic cell novel novel strategies novel therapeutic intervention programs response single-cell RNA sequencing standard of care therapeutic target therapy resistant transcriptome transcriptome sequencing translational scientist transplant model treatment response tumor tumor microenvironment tumor progression tumor-immune system interactions

项目摘要

Abstract Unlike many cancers, pancreatic ductal adenocarcinoma (PDAC) is characterized by a hypoxic, nutrient- deprived, immunosuppressive tumor microenvironment (TME) and a fibrotic stroma that may impair treatment response. Recent single-cell studies suggest a complex interplay between malignant tumor cells and other cell types within the TME, with crosstalk between tumor and stromal cell types influencing malignant cell phenotypes, including responses to therapy. Understanding these interactions will provide insight into PDAC progression and therapy resistance. In particular, cancer-associated fibroblasts (CAFs) are a major non-immune cell component of the TME and are comprised of several distinct subtypes that vary based on tumor subtype and the surrounding microenvironmental niche. In this proposal, we bring together a multidisciplinary team of basic and translational investigators that will build upon our prior studies to investigate the Tumor-TME co-organizer model with a focus on interrogating interactions between PDAC tumor cells and CAFs in the TME. Specifically, we will examine the overarching hypothesis that reciprocal signaling between tumor cells and CAFs shapes malignant cell and CAF phenotypes in a context-specific manner that can be modulated by prior therapy and the organ-specific niche. We will leverage multiple built-in capabilities, including genetically engineered mouse models (GEMMs), patient- derived organoid (PDO) and matched fibroblast models, functional genetic screens and clinical trials with serial biopsies to study the PDAC TME continuum in disease progression and resistance to therapy. Specifically, we propose (1) to determine whether targeting organ-specific PDAC-CAF interactions enhances therapeutic responses, (2) to interrogate novel vulnerabilities resulting from tumor cell and CAF reprogramming during PDAC therapy, and (3) investigate whether TGFB blockade disrupts tumor cell-CAF crosstalk and sensitizes PDAC to chemotherapy. In pursuing these studies, we will work with other members of the PDAC Stromal Reprogramming Consortium (PSRC) to pursue collaborative studies to understand how PDAC and TME interactions program tumor progression and therapy responses.

摘要